Pembrolizumab monotherapy has been shown to be effective in a small cohort of heavily pretreated patients with ER+/HER2− metastatic breast cancer [42] and demonstrated meaningful antitumor activity in cancers with high TMB, including ER+/HER2− breast cancers [43]. This evidence concerns the gene ESR1 and breast cancer.